Clinical Trials
6
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:1
Phase 2:2
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (50.0%)Phase 2
2 (33.3%)Phase 1
1 (16.7%)A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Repligen Corporation
- Target Recruit Count
- 180
- Registration Number
- NCT00812058
- Locations
- 🇺🇸
Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham, Alabama, United States
🇺🇸K&S Professional Research Services, Little Rock, Arkansas, United States
🇺🇸Affiliated Research Institute, San Diego, California, United States
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Phase 3
Completed
- Conditions
- Pancreatitis
- Interventions
- Drug: RG1068 (synthetic human secretin)
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Repligen Corporation
- Target Recruit Count
- 258
- Registration Number
- NCT00660335
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
Phase 2
Completed
- Conditions
- Bipolar Depression
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2007-11-09
- Lead Sponsor
- Repligen Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT00322764
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Carman Research, Smyrna, Georgia, United States
🇺🇸Indiana University-Purdue University Indianapolis, Indianapolis, Indiana, United States
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
Phase 1
Terminated
- Conditions
- Mitochondrial Diseases
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2005-08-05
- Lead Sponsor
- Repligen Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT00060515
Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
Phase 3
Terminated
- Conditions
- Autism
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2005-11-21
- Lead Sponsor
- Repligen Corporation
- Registration Number
- NCT00036231
- Prev
- 1
- 2
- Next
News
No news found